Modeling Serotonergic Signaling Deficits in Alzheimer’s Hindbrain Organoids

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Alzheimer’s & Dementia https://doi.org/10.1002/alz.71273
Dr. Rachel J. Boyd et al.

Points

Researchers utilized induced pluripotent stem cells from Alzheimer’s patients to generate hundreds of hindbrain organoids which serve as specialized models for studying serotonin signaling and individualized drug efficacy.
The study identified that diseased organoids possess significantly lower levels of essential proteins like RAB3A and NSF which are vital for healthy communication between neurons and memory function.
Experimental results showed that treating organoids with the antidepressant escitalopram increased signaling proteins in some patient samples while others exhibited absolutely no molecular response to the drug.
Extracellular vesicles secreted by the lab-grown tissues were found to carry unique protein signatures that could eventually function as a liquid biopsy to diagnose distinct Alzheimer’s subtypes.
These findings suggest that brain organoids can successfully identify which patient subgroups are most likely to benefit from specific medications to help create precise and targeted clinical treatments.

Summary

This study evaluated the clinical utility of patient-derived hindbrain organoids to model Alzheimer’s disease (AD) heterogeneity and individual pharmacological responses. By reprogramming blood-derived induced pluripotent stem cells (iPSCs) into self-organizing serotonergic neural clusters, the researchers established a high-throughput platform to analyze molecular signatures associated with AD. The investigation sought to determine if proteomic changes in these organoids and their secreted extracellular vesicles (EVs) could accurately reflect disease pathology and predict the efficacy of the selective serotonin reuptake inhibitor (SSRI) escitalopram oxalate.

The analysis revealed that AD-derived organoids exhibit distinct proteomic deficits compared to healthy controls, specifically regarding proteins critical for synaptic signaling and neurotransmitter release, such as RAB3A, NSF, and ATCAY. Upon exposure to escitalopram, significant therapeutic heterogeneity was observed across the samples. In responsive organoids, the treatment successfully upregulated proteins involved in serotonin signaling and synaptic communication; however, other patient-derived tissues showed minimal to no proteomic shift. This variability suggests that individualized molecular profiles govern drug sensitivity, mirroring the clinical challenges of AD treatment.

The findings suggest that the protein content of organoid-secreted EVs serves as a reliable liquid biopsy for assessing disease staging and drug response. These vesicles carry molecular cargo involved in memory and neuroinflammation, providing a systems-level view of pathophysiology without invasive brain tissue sampling. While the study demonstrates the dual-platform’s feasibility for precision medicine, the researchers aim to incorporate immune and vascular networks in future models to enhance physiological fidelity. These preliminary steps provide a scalable framework for identifying patient subgroups likely to benefit from targeted neuropsychiatric interventions.

Link to the article: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71273

References

Boyd, R. J., Dong, D., Sagar, R., Iliuk, A., Ahmed, W., Androni, X., Porsteinsson, A. P., Rosenberg, P. B., Lyketsos, C. G., Witwer, K. W., & Mahairaki, V. (2026). Proteomic profiling of brain organoids and extracellular vesicles identifies early Alzheimer’s disease biomarkers and drug response heterogeneity. Alzheimer’s & Dementia, 22(4), e71273. https://doi.org/10.1002/alz.71273